We also demonstrated the characteristics and functionality of these MSLN.CAR-IL-15 iNK cells through comprehensive in vitro and in vivo experiments, including validating CAR expression and profiling iNK cell biomarkers, and demonstrated the tumor killing efficacy of these engineered iNK cells against MSLN-positive solid tumors. This evidence concerns the gene IL15 and neoplasm.